MicroRNA expression profile associated with 3 response to neoadjuvant chemoradiotherapy in 4 locally advanced rectal cancer patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000377" target="_blank" >RIV/00209805:_____/12:#0000377 - isvavai.cz</a>
Result on the web
<a href="http://www.ro-journal.com/content/7/1/195" target="_blank" >http://www.ro-journal.com/content/7/1/195</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/1748-717X-7-195" target="_blank" >10.1186/1748-717X-7-195</a>

Result language
angličtina
Original language name
MicroRNA expression profile associated with 3 response to neoadjuvant chemoradiotherapy in 4 locally advanced rectal cancer patients
Original language description
Background: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present the new predictive biomarkers for rectal cancer patients. Methods: We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were compared using large-scale miRNA expression profiling. Results: Express
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT13860" target="_blank" >NT13860: Analysis of EGFR signalling and microRNA expression profiles in prediction of response to anti-EGFR therapy in colorectal cancer patients with wild-type KRAS</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)